ASTRANA HEALTH INC (ASTH) Stock Fundamental Analysis
NASDAQ:ASTH - US03763A2078 - Common Stock
31.96 USD
+0.63 (+2.01%)
31.96 USD
0 (0%)
Overall ASTH gets a fundamental rating of 5 out of 10. We evaluated ASTH against 102 industry peers in the Health Care Providers & Services industry. ASTH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ASTH is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
In the past year ASTH was profitable.
ASTH had a positive operating cash flow in the past year.
In the past 5 years ASTH has always been profitable.
ASTH had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
ASTH's Return On Assets of 1.75% is in line compared to the rest of the industry. ASTH outperforms 55.88% of its industry peers.
Looking at the Return On Equity, with a value of 3.30%, ASTH is in line with its industry, outperforming 57.84% of the companies in the same industry.
ASTH's Return On Invested Capital of 4.50% is in line compared to the rest of the industry. ASTH outperforms 54.90% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ASTH is below the industry average of 9.14%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.75% | ||
| ROE | 3.3% | ||
| ROIC | 4.5% |
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
1.3 Margins
With a Profit Margin value of 1.04%, ASTH perfoms like the industry average, outperforming 56.86% of the companies in the same industry.
ASTH's Profit Margin has declined in the last couple of years.
ASTH has a Operating Margin (2.90%) which is comparable to the rest of the industry.
In the last couple of years the Operating Margin of ASTH has declined.
ASTH's Gross Margin of 11.30% is on the low side compared to the rest of the industry. ASTH is outperformed by 71.57% of its industry peers.
In the last couple of years the Gross Margin of ASTH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.9% | ||
| PM (TTM) | 1.04% | ||
| GM | 11.3% |
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
2. Health
2.1 Basic Checks
ASTH has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
ASTH has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, ASTH has a worse debt to assets ratio.
2.2 Solvency
ASTH has an Altman-Z score of 3.77. This indicates that ASTH is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of ASTH (3.77) is better than 71.57% of its industry peers.
ASTH has a debt to FCF ratio of 3.41. This is a good value and a sign of high solvency as ASTH would need 3.41 years to pay back of all of its debts.
ASTH's Debt to FCF ratio of 3.41 is fine compared to the rest of the industry. ASTH outperforms 77.45% of its industry peers.
A Debt/Equity ratio of 0.52 indicates that ASTH is somewhat dependend on debt financing.
With a decent Debt to Equity ratio value of 0.52, ASTH is doing good in the industry, outperforming 60.78% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.41 | ||
| Altman-Z | 3.77 |
ROIC/WACC0.54
WACC8.36%
2.3 Liquidity
A Current Ratio of 1.59 indicates that ASTH should not have too much problems paying its short term obligations.
ASTH has a Current ratio (1.59) which is in line with its industry peers.
A Quick Ratio of 1.59 indicates that ASTH should not have too much problems paying its short term obligations.
The Quick ratio of ASTH (1.59) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.59 |
3. Growth
3.1 Past
ASTH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -64.58%.
ASTH shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 19.19% yearly.
Looking at the last year, ASTH shows a very strong growth in Revenue. The Revenue has grown by 51.97%.
The Revenue has been growing by 38.01% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-64.58%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-52.5%
Revenue 1Y (TTM)51.97%
Revenue growth 3Y38.01%
Revenue growth 5YN/A
Sales Q2Q%34.66%
3.2 Future
The Earnings Per Share is expected to grow by 31.87% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 20.51% on average over the next years. This is a very strong growth
EPS Next Y47.59%
EPS Next 2Y52.93%
EPS Next 3Y43.91%
EPS Next 5Y31.87%
Revenue Next Year61.45%
Revenue Next 2Y43.14%
Revenue Next 3Y30.14%
Revenue Next 5Y20.51%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 62.67 indicates a quite expensive valuation of ASTH.
Compared to the rest of the industry, the Price/Earnings ratio of ASTH is on the same level as its industry peers.
When comparing the Price/Earnings ratio of ASTH to the average of the S&P500 Index (27.08), we can say ASTH is valued expensively.
With a Price/Forward Earnings ratio of 15.35, ASTH is valued correctly.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ASTH indicates a somewhat cheap valuation: ASTH is cheaper than 73.53% of the companies listed in the same industry.
ASTH's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.72.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 62.67 | ||
| Fwd PE | 15.35 |
4.2 Price Multiples
ASTH's Enterprise Value to EBITDA ratio is in line with the industry average.
Based on the Price/Free Cash Flow ratio, ASTH is valued cheaper than 81.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.16 | ||
| EV/EBITDA | 16.78 |
4.3 Compensation for Growth
ASTH's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as ASTH's earnings are expected to grow with 43.91% in the coming years.
PEG (NY)1.32
PEG (5Y)3.27
EPS Next 2Y52.93%
EPS Next 3Y43.91%
5. Dividend
5.1 Amount
ASTH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
31.96
+0.63 (+2.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners53.19%
Inst Owner ChangeN/A
Ins Owners9.76%
Ins Owner Change1.29%
Market Cap1.60B
Analysts83.53
Price Target44.77 (40.08%)
Short Float %4.13%
Short Ratio4.32
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.09
Dividend Growth(5Y)N/A
DP33.15%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-46.54%
Min EPS beat(2)-48.7%
Max EPS beat(2)-44.39%
EPS beat(4)1
Avg EPS beat(4)-79.13%
Min EPS beat(4)-225.16%
Max EPS beat(4)1.74%
EPS beat(8)5
Avg EPS beat(8)-25.47%
EPS beat(12)8
Avg EPS beat(12)-7.32%
EPS beat(16)11
Avg EPS beat(16)2.37%
Revenue beat(2)1
Avg Revenue beat(2)-1.49%
Min Revenue beat(2)-3.56%
Max Revenue beat(2)0.57%
Revenue beat(4)3
Avg Revenue beat(4)1.04%
Min Revenue beat(4)-3.56%
Max Revenue beat(4)5.66%
Revenue beat(8)5
Avg Revenue beat(8)0.88%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.49%
PT rev (3m)-13.09%
EPS NQ rev (1m)-1.07%
EPS NQ rev (3m)28.83%
EPS NY rev (1m)7.82%
EPS NY rev (3m)5.16%
Revenue NQ rev (1m)8.18%
Revenue NQ rev (3m)33.78%
Revenue NY rev (1m)9.99%
Revenue NY rev (3m)18.34%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 62.67 | ||
| Fwd PE | 15.35 | ||
| P/S | 0.66 | ||
| P/FCF | 13.16 | ||
| P/OCF | 12.22 | ||
| P/B | 2.08 | ||
| P/tB | 6.57 | ||
| EV/EBITDA | 16.78 |
EPS(TTM)0.51
EY1.6%
EPS(NY)2.08
Fwd EY6.51%
FCF(TTM)2.43
FCFY7.6%
OCF(TTM)2.61
OCFY8.18%
SpS48.45
BVpS15.33
TBVpS4.86
PEG (NY)1.32
PEG (5Y)3.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.75% | ||
| ROE | 3.3% | ||
| ROCE | 7.13% | ||
| ROIC | 4.5% | ||
| ROICexc | 6.9% | ||
| ROICexgc | 37.52% | ||
| OM | 2.9% | ||
| PM (TTM) | 1.04% | ||
| GM | 11.3% | ||
| FCFM | 5.01% |
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
ROICexc(3y)11.13%
ROICexc(5y)11.73%
ROICexgc(3y)50.18%
ROICexgc(5y)49.73%
ROCE(3y)11.21%
ROCE(5y)11.68%
ROICexcg growth 3Y-13.47%
ROICexcg growth 5YN/A
ROICexc growth 3Y-16.27%
ROICexc growth 5YN/A
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
F-Score5
Asset Turnover1.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.41 | ||
| Debt/EBITDA | 4.04 | ||
| Cap/Depr | 31.97% | ||
| Cap/Sales | 0.39% | ||
| Interest Coverage | 8.53 | ||
| Cash Conversion | 131.6% | ||
| Profit Quality | 480.02% | ||
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.59 | ||
| Altman-Z | 3.77 |
F-Score5
WACC8.36%
ROIC/WACC0.54
Cap/Depr(3y)106.76%
Cap/Depr(5y)87.27%
Cap/Sales(3y)1.49%
Cap/Sales(5y)1.42%
Profit Quality(3y)99.59%
Profit Quality(5y)98.35%
High Growth Momentum
Growth
EPS 1Y (TTM)-64.58%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-52.5%
EPS Next Y47.59%
EPS Next 2Y52.93%
EPS Next 3Y43.91%
EPS Next 5Y31.87%
Revenue 1Y (TTM)51.97%
Revenue growth 3Y38.01%
Revenue growth 5YN/A
Sales Q2Q%34.66%
Revenue Next Year61.45%
Revenue Next 2Y43.14%
Revenue Next 3Y30.14%
Revenue Next 5Y20.51%
EBIT growth 1Y-26.57%
EBIT growth 3Y-3.09%
EBIT growth 5YN/A
EBIT Next Year96.88%
EBIT Next 3Y48.82%
EBIT Next 5Y33.37%
FCF growth 1Y11.26%
FCF growth 3Y-4.75%
FCF growth 5YN/A
OCF growth 1Y-23.49%
OCF growth 3Y-9.46%
OCF growth 5YN/A